Welcome to Phoenix Rising!
Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To become a member, simply click the Register button at the top right.
Kati and Barb: Well, I guess I understand, especially Kati, considering your mom's situation, and Barb, who comes from a nursing background (?). Very sorry about your mom Kati.
At the same time you're both reading far too much into what I asked or said (coffee enemas?!). I'm not saying drugs are out of the question, or never necessary, but to ignore the methylation issues (found in almost every CFS patient so far), how carnitine helps with mitochondrial issues, omega 3's help with circulation and inflammation, etc. not to mention ignoring the obvious changes in what we eat compared to 50-60 years ago...well, I guess we'll have to agree to disagree, and wish each other well.
And Sasha -- that's great to hear about Bob. I'm amazed he survived, and glad to hear he's eating again.
Hemispherx Biopharma Announces Financial Results for the Three Months Ended June 30, 2013
PHILADELPHIA, Aug. 9, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the three months ended June 30, 2013. The net loss (including non-cash effects) was approximately $4,283,000 or $(0.03) per share as compared to a net loss of $3,000,000 or ($0.02) per share for the same three month period in 2012. This Quarter-to-Quarter increase in net loss of approximately $1,283,000 was predominantly caused by:
Read more... linked in title above.
- a non-cash write-down of existing Alferon N Injection® work in process inventory for $458,000; and
- an increase of approximately $470,000 related to continued efforts to seek regulatory approval (U.S.A. and abroad) of the Ampligen® NDA for Chronic Fatigue Syndrome including costs related to clinical studies, research, raw material production and various GMP validation procedures at our New Brunswick, NJ facility.
PRESS RELEASE
March 19, 2014
Hemispherx Biopharma, Inc. to Present Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference
Hemispherx Biopharma, Inc. to Present Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference
PHILADELPHIA, March 19, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) will participate in the 11th Biennial International Research and Clinical Conference to be held in San Francisco, California, USA, March 20-23, 2014. The title of the presentation is "Differential Exercise Responses to Rintatolimod [Ampligen(R)] Exhibited by Patients with Severe Chronic Fatigue Syndrome (CFS)". This Phase III prospective, double-blind, randomized, placebo-controlled trial was conducted at twelve centers by leading researchers in fatigue and post-exertional fatigue.
...
http://online.wsj.com/article/PR-CO-20140319-906721.html